, Volume 38, Issue 2, pp 235–242 | Cite as

Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?

  • Núria Vilarrasa
  • Joan Vendrell
  • Javier Maravall
  • Iñaki Elío
  • Esther Solano
  • Patricia San José
  • Isabel García
  • Núria Virgili
  • Juan Soler
  • José Manuel Gómez
Original Article


To analyse in a cohort of healthy subjects and in a group of morbidly obese patients, we studied the association amongst 25(OH) D and plasma concentrations of adipocytokines, inflammatory cytokines and insulin resistance. We also aimed to determine whether vitamin D-deficient patients showed a greater inflammatory profile. In the observational study that the authors conducted, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin and interleukine-18 were determined in 134 healthy men and 127 women. In the population consisting of 44 patients with morbid obesity, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 and C-reactive protein were analysed. In the healthy population, plasma 25(OH) D showed a negative correlation with body mass index, body fat, waist, hip circumference and with leptin. However, no significant associations were found amongst 25(OH) D and plasma concentrations of resistin, adiponectin or interleukine-18. Patients with vitamin D deficiency showed higher body mass index, fat mass percentage and higher leptin concentrations compared with subjects with normal 25(OH) D concentrations. In the morbidly obese subjects, 25(OH) D did not correlate with leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 or with C-reactive protein. In patients with morbid obesity, no differences were found in adipokines and inflammatory cytokines concentrations regarding 25(OH) D status. No associations were found either between 25(OH) D and plasma glucose and insulin resistance or with lipid profile. Plasma 25(OH) D concentrations are associated with adiposity markers but not with adipocytokines implicated in inflammation. This lack of association does not support a major role of 25(OH) D in the pro-inflammatory environment observed in morbidly obese subjects. In addition, subjects with vitamin D deficiency are not characterized by a greater inflammatory state.


Adiponectin Adipocytokines Inflammatory cytokines Insulin resistance Morbidly obesity Vitamin D 


Declaration of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.


This study was supported by the CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), a project of Instituto de Salud Carlos III, ISCIII.


  1. 1.
    M.F. Holick, Vitamin D: a millennium perspective. J. Cell. Biochem. 88, 296–307 (2003)CrossRefPubMedGoogle Scholar
  2. 2.
    M.F. Holick, Vitamin D deficiency. N. Engl. J. Med. 357, 266–281 (2007)CrossRefPubMedGoogle Scholar
  3. 3.
    M.F. Holick, The role of vitamin D for bone health and fracture prevention. Curr. Osteoporos. Rep. 4, 96–102 (2006)CrossRefPubMedGoogle Scholar
  4. 4.
    R.P. Heany, The Vitamin D requirement in health and disease. J. Steroid Biochem. Mol. Biol. 97, 13–19 (2005)CrossRefGoogle Scholar
  5. 5.
    M.T. Cantorna, Y. Zhu, M. Froicu, A. Wittke, Vitamin D status, 1,25-dihidroxyvitamin D3, and the immune system. Am. J. Clin. Nutr. 80, 1717s–1720s (2004)PubMedGoogle Scholar
  6. 6.
    H.F. Deluca, M.T. Cantorna, Vitamin D: its role and uses in immunology. FASEB J. 15, 2579–2585 (2001)CrossRefPubMedGoogle Scholar
  7. 7.
    D. Bikle, Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 94, 26–34 (2009)CrossRefPubMedGoogle Scholar
  8. 8.
    H. Ishida, A.W. Norman, Demonstration of a high affinity receptor for 1,25-dihydroxyvitamin D3 in a rat pancreas. Mol. Cell. Endocrinol. 60, 109–117 (1988)CrossRefPubMedGoogle Scholar
  9. 9.
    J.A. Johnson, J.P. Grande, P.C. Roche, R. Kumar, Immunohistochemical localization of the 1, 25 (OH)2 D3 receptor and calbindin D28k in human and rat pancreas. Am. J. Physiol. 267, E356–E360 (1994)PubMedGoogle Scholar
  10. 10.
    S. Chen, G.P. Sims, X.X. Chen, Y.Y. Gu, S. Chen, P.E. Lipsky, Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179, 1634–1647 (2007)PubMedGoogle Scholar
  11. 11.
    J.M. Lemire, D.C. Archer, L. Beck, H.L. Spiegelberg, Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr. 125, 1704S–1708S (1995)PubMedGoogle Scholar
  12. 12.
    D. Mauricio, T. Mandrup-Poulsen, J. Nerup, Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes Metab. Rev. 12, 57–68 (1996)PubMedGoogle Scholar
  13. 13.
    J.M. Lemire, Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 53, 599–602 (1995)CrossRefPubMedGoogle Scholar
  14. 14.
    L. Overbergh, B. Decallonne, D. Valckx, A. Verstuf, J. Depovere, J. Laureys, O. Rutgeerts, R. Saint-Arnaud, R. Bouillon, C. Mathieu, Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin. Exp. Immunol. 120, 139–146 (2000)CrossRefPubMedGoogle Scholar
  15. 15.
    C.A. Peterson, M.E. Heffernan, Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH) D concentrations in healthy women. J. Inflamm. 5, 10–19 (2008)CrossRefGoogle Scholar
  16. 16.
    S.S. Schleithoff, A. Zittermann, G. Tenderich, H.K. Berthold, P. Stehle, R. Koefer, Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83, 754–759 (2006)PubMedGoogle Scholar
  17. 17.
    S. Türk, M. Akbulut, A. Yildiz, M. Gürbilek, S. Gönen, Z. Tombol, M. Yeksan, Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 90, 188–194 (2002)CrossRefPubMedGoogle Scholar
  18. 18.
    J.S. Yudkin, C.D. Stehouwer, J.J. Emeis, S.W. Coppack, C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler. Thromb. Vasc. Biol. 19, 972–978 (1999)PubMedGoogle Scholar
  19. 19.
    X. Palomer, J.M. González-Clemente, F. Blanco-Vaca, D. Mauricio, Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes. Metab. 10, 185–197 (2008)CrossRefPubMedGoogle Scholar
  20. 20.
    K.C. Chiu, A. Chu, V.L. Go, M.F. Saad, Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am. J. Clin. Nutr. 79, 820–825 (2004)PubMedGoogle Scholar
  21. 21.
    M.A. Pereira, D.R. Jacobs, L. Van Horn, M.L. Slattery, A.I. Kartashov, D.S. Ludwig, Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 287, 2081–2089 (2002)CrossRefPubMedGoogle Scholar
  22. 22.
    E.S. Ford, U.A. Ajani, L.C. Mc Guire, S. Liu, Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 28, 1228–1230 (2005)CrossRefPubMedGoogle Scholar
  23. 23.
    U.G. Kyle, I. Bosaeus, A.D. De Lorenzo, P. Deurenberg, M. Elia, J.M. Gómez, B. Lilienthal Heitmann, L. Kent-Smith, J.C. Melchior, M. Pirlich, H. Scharfetter, M.W.J. Schols A, C. Pichard, Bioelectrical impedance analysis, Part II: utilization in clinical practice. Clin. Nutr. 23, 1430–1453 (2004)CrossRefPubMedGoogle Scholar
  24. 24.
    World Health Organization, Obesity: preventing and managing the global epidemic. Report on a WHO consultation on obesity. WHO/NUT/NCD/98.1. WHO, Geneva, 3–5 June 1997Google Scholar
  25. 25.
    D.T. Villareal, R. Citivelli, A. Chines, L.V. Avioli, Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J. Clin. Endocrinol. Metab. 72, 628–634 (1991)CrossRefPubMedGoogle Scholar
  26. 26.
    M.K. Thomas, D.M. Lloyd-Jones, R.I. Thadhani, A.C. Shaw, D.J. Deraska, B.T. Kitch, E.C. Vamvakas, I.M. Dick, R.L. Prince, J.S. Fikelstein, Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777–783 (1998)CrossRefPubMedGoogle Scholar
  27. 27.
    C. Menendez, M. Lage, R. Peino, R. Baldelli, P. Concheiro, C. Diéguez, F.F. Casanueva, Retinoid acid and vitamin D3 powerfully inhibit in vitro leptin secretion by human adipose tissue. J. Endocrinol. 170, 425–431 (2001)CrossRefPubMedGoogle Scholar
  28. 28.
    C.L. McTernan, P.G. McTernan, A.L. Harte, P.L. Levick, A.H. Barnett, S. Kumar, Resistin central obesity and type 2 diabetes. Lancet 35, 46–47 (2002)CrossRefGoogle Scholar
  29. 29.
    M. Filková, M. Haluzík, S. Gay, L. Senolt, The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin. Immunol. 133, 157–170 (2009)CrossRefPubMedGoogle Scholar
  30. 30.
    M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, A. Tarkowski, Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174, 5789–5795 (2005)PubMedGoogle Scholar
  31. 31.
    X. Sun, M.B. Zemel, Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity 15, 340–348 (2007)CrossRefPubMedGoogle Scholar
  32. 32.
    M.T. Cantorna, B.D. Mahon, D-hormone and the immune system. J. Rheumatol. 76, 11–20 (2005)Google Scholar
  33. 33.
    E. Liu, J.B. Meigs, A.G. Pittas, N.M. Mc Keown, C.D. Economos, S.L. Booth, P.F. Jacques, Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J. Nutr. 139, 329–334 (2009)PubMedGoogle Scholar
  34. 34.
    M.H. Gannagé-Yared, R. Chedid, S. Khalife, E. Azzi, F. Zoghbi, G. Halaby, Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur. J. Endocrinol. 160, 965–971 (2009)CrossRefPubMedGoogle Scholar
  35. 35.
    J.J. Diez, P. Iglesias, The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148, 293–300 (2003)CrossRefPubMedGoogle Scholar
  36. 36.
    A. Zittermann, S. Frisch, H.K. Berthold, C. Götting, J. Kuhn, K. Kleesiek, P. Stehle, H. Koertke, R. Koerfer, Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am. J. Clin. Nutr. 89, 1321–1327 (2009)CrossRefPubMedGoogle Scholar
  37. 37.
    D. Aderka, H. Engelmann, Y. Maor, C. Brakebusch, D. Wallach, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175, 323–329 (1992)CrossRefPubMedGoogle Scholar
  38. 38.
    J.P. Bastard, C. Jardel, E. Bruckert, H. Vidal, B. Hainque, Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes. Metab. 2, 323–325 (2000)CrossRefPubMedGoogle Scholar
  39. 39.
    B. Zahorska-Markiewicz, J. Janowska, M. Olszanecka-Glinianowicz, A. Zurakowski, Serum concentrations of TNF-α and soluble TNF-α receptors in obesity. Int. J. Obes Relat. Metab. Disord. 24, 1392–1395 (2000)CrossRefPubMedGoogle Scholar
  40. 40.
    M. Olszanecka-Glinianowicz, B. Zahorska-Markiewicz, J. Janowska, The effect of weight loss on serum concentrations of nitric oxide, TNF-alpha and TNF-alpha receptors. Pol. J. Endocrinol. 57, 487–493 (2006)Google Scholar
  41. 41.
    C.A. Dinarello, Interleukin-18: a proinflammatory cytokine. Eur. Cytokine Netw. 11, 483–486 (2000)PubMedGoogle Scholar
  42. 42.
    I.B. Mc Innes, J.A. Gracie, B.P. Leung, X.Q. Wei, F.Y. Liew, Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol. Today 21, 312–315 (2000)CrossRefGoogle Scholar
  43. 43.
    N. Vilarrasa, J. Vendrell, R. Sanchez-Santos, M. Broch, A. Megia, C. Masdevall, N. Gomez, J. Soler, J. Pujol, C. Bettonica, H. Aanda, J.M. Gómez, Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, c-reactive protein and adiponectin in morbidly obese patients. Clin. Endocrinol. (Oxf) 67, 679–686 (2007)CrossRefGoogle Scholar
  44. 44.
    N. Vilarrasa, J.M. Gómez, C. Masdevall, J. Pujol, J. Soler, I. Elio, L. Gallart, J. Vendrell, Study of the relationship between adiponectin, interleukin-18, ghrelin and bone mineral density in morbidly obese women after gastric by-pass. Endocrinol. Nutr. 56, 355–360 (2009)CrossRefPubMedGoogle Scholar
  45. 45.
    Z. Mallat, A. Corbaz, A. Scoazec, S. Besnard, G. Lesèche, Y. Chvatchko, A. Tedgui, Expression of Interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104, 1598–1603 (2001)CrossRefPubMedGoogle Scholar
  46. 46.
    Z. Mallat, A. Corbaz, A. Scoazec, P. Graber, S. Alouani, B. Esposito, Y. Humbert, Y. Chvatchko, A. Tedgui, Interleukin-18/interleukin-18 binding protein signalling modulates atherosclerotic lesion development and stability. Circ. Res. 89, E41–E45 (2001)CrossRefPubMedGoogle Scholar
  47. 47.
    D.T. Ngo, A.L. Sverdlov, J.J. McNeil, J.D. Horowitz, Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Am. J. Med. 123, 335–341 (2010)CrossRefPubMedGoogle Scholar
  48. 48.
    R. Jorde, M. Sneve, P.A. Torjesen, Y. Figenschau, L.G. Gøransson, R. Omdal, No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 50, 175–180 (2010)CrossRefPubMedGoogle Scholar
  49. 49.
    E.D. Michos, E.A. Streeten, K.A. Ryan, E. Rampersaud, P.A. Peyser, L.F. Bielak, A.R. Shuldiner, B.D. Mitchell, W. Post, Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the old order Amish. Calcif. Tissue Int. 84, 423–424 (2009)CrossRefGoogle Scholar
  50. 50.
    G. Isaia, R. Giordano, S. Adami, High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24, 1496 (2001)CrossRefPubMedGoogle Scholar
  51. 51.
    A.G. Pittas, J. Lau, F.B. Hu, B. Dawson-Hughes, The role of vitamin d and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92, 2017–2029 (2007)CrossRefPubMedGoogle Scholar
  52. 52.
    S.E. Shoelson, L. Herrero, A. Naaz, Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2180 (2007)CrossRefPubMedGoogle Scholar
  53. 53.
    J.I. Botella-Carretero, F. Alvarez-Blasco, J.J. Villafruela, J.A. Balsa, C. Vázquez, H.F. Escobar-Morreale, Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin. Nutr. 26, 573–580 (2007)CrossRefPubMedGoogle Scholar
  54. 54.
    S. Rueda, C. Fernández-Fernández, F. Romero, J. Martínez de Osaba, J. Vidal, Vitamin D, PTH and the metabolic syndrome in severely obese subjects. Obes. Surg. 18, 151–154 (2008)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Núria Vilarrasa
    • 1
    • 2
  • Joan Vendrell
    • 2
    • 3
  • Javier Maravall
    • 1
    • 2
  • Iñaki Elío
    • 1
    • 2
  • Esther Solano
    • 2
    • 3
  • Patricia San José
    • 1
    • 2
  • Isabel García
    • 1
    • 2
  • Núria Virgili
    • 1
    • 2
  • Juan Soler
    • 1
    • 2
  • José Manuel Gómez
    • 1
    • 2
    • 4
  1. 1.Endocrinology and Diabetes UnitHospital Universitari de BellvitgeL’Hospitalet de Llobregat, BarcelonaSpain
  2. 2.CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)BarcelonaSpain
  3. 3.Unitat de RecercaHospital Universitari de Tarragona Joan XXIIITarragonaSpain
  4. 4.BarcelonaSpain

Personalised recommendations